Panel advises against rimonabant approval.
Traynor
Kate
K
D026683:Advisory Committees / Q000331:legislation & jurisprudence*; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D009765:Obesity / Q000188:drug therapy / Q000523:psychology; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000077285:Rimonabant; D014481:United States
D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant